BIO-FD&CLtd Past Earnings Performance
Past criteria checks 4/6
BIO-FD&CLtd has been growing earnings at an average annual rate of 20%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 13.1% per year. BIO-FD&CLtd's return on equity is 8.3%, and it has net margins of 31.7%.
Key information
20.0%
Earnings growth rate
16.3%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 13.1% |
| Return on equity | 8.3% |
| Net Margin | 31.7% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How BIO-FD&CLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 16,067 | 5,099 | 3,943 | 2,026 |
| 30 Jun 24 | 16,397 | 5,164 | 4,366 | 1,627 |
| 31 Mar 24 | 16,059 | 5,808 | 4,285 | 1,452 |
| 31 Dec 23 | 15,592 | 5,585 | 4,323 | 1,429 |
| 30 Sep 23 | 14,947 | 4,725 | 4,587 | 1,088 |
| 30 Jun 23 | 13,988 | 4,337 | 4,128 | 1,326 |
| 31 Mar 23 | 14,832 | 5,120 | 4,258 | 1,467 |
| 31 Dec 22 | 15,855 | 4,335 | 4,538 | 1,449 |
| 30 Sep 22 | 16,368 | 3,874 | 4,331 | 1,256 |
| 30 Jun 22 | 15,881 | 3,691 | 4,400 | 990 |
| 31 Mar 22 | 14,092 | 2,517 | 3,534 | 1,285 |
| 31 Dec 21 | 11,972 | 2,908 | 2,959 | 816 |
| 30 Sep 21 | 9,467 | 2,511 | 2,506 | 818 |
| 31 Dec 20 | 8,640 | 2,461 | 1,799 | 739 |
| 31 Dec 19 | 8,476 | 2,562 | 1,623 | 937 |
| 31 Dec 18 | 5,998 | 394 | 1,309 | 1,255 |
| 31 Dec 16 | 4,610 | 695 | 1,299 | 927 |
| 31 Dec 15 | 3,977 | 891 | 879 | 603 |
Quality Earnings: A251120 has high quality earnings.
Growing Profit Margin: A251120's current net profit margins (31.7%) are higher than last year (31.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A251120's earnings have grown significantly by 20% per year over the past 5 years.
Accelerating Growth: A251120's earnings growth over the past year (7.9%) is below its 5-year average (20% per year).
Earnings vs Industry: A251120 earnings growth over the past year (7.9%) exceeded the Biotechs industry 7.9%.
Return on Equity
High ROE: A251120's Return on Equity (8.3%) is considered low.